SLC22A17 and gastric adenocarcinoma: Figure 3A shows that hub DEIRGs (e.g., PROCR (p = 0.039), S100A12 (p = 0.019), SLC22A17 (p = 0.011)) significantly affected the overall survival outcomes of STAD patients.